Claims for Patent: 10,227,342

Summary for Patent: 10,227,342

Title:	Heteroaryl compounds for kinase inhibition
Abstract:	Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
Inventor(s):	Huang; Wei-Sheng (Acton, MA), Gong; Yongjin (Belmont, MA), Li; Feng (Winchester, MA), Bencivenga; Nicholas E. (Malden, MA), Dalgarno; David C. (Brookline, MA), Kohlmann; Anna (Winchester, MA), Shakespeare; William C. (Southborough, MA), Thomas; Ranny M. (Sharon, MA), Zhu; Xiaotian (Newton, MA), West; Angela (Franklin, MA), Youngsaye; Willmen (Boston, MA), Zhang; Yun (Acton, MA), Zhou; Tianjun (Belmont, MA)
Assignee:	ARIAD PHARMACEUTICALS, INC. (Cambridge, MA)
Application Number:	15/319,637
Patent Claims:	1. A compound of Formula I, or a pharmaceutically acceptable form thereof: ##STR01262## wherein: A is selected from ##STR01263## X.sub.1 is carbon substituted by a group selected from ##STR01264## X.sub.2 is selected from N and CR.sub.2; X.sub.3 is selected from N and CR.sub.4; each X.sub.4 is independently selected from N and CR.sub.7; X.sub.5 is selected from N and CR.sub.8; X.sub.6 is selected from N and CR.sub.9; each R.sub.1 is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, each of which is substituted with 0, 1, 2, or 3 R.sub.12; R.sub.1' is selected from H and alkyl, each of which is substituted with 0, 1, 2, or 3 R.sub.12; R.sub.2, R.sub.3, and R.sub.4 are each independently selected from H, alkyl, alkoxy, halo, ON, and NO.sub.2, each of which is substituted with 0, 1, 2, or 3 R.sub.12; R.sub.5 is selected from H, alkyl, alkenyl, alkynyl, --NR.sub.10R.sub.11, --OR.sub.11, and --SR.sub.11, each of which is independently substituted with 0, 1, 2, or 3 R.sub.12; or when R.sub.5 is --NR.sub.10R.sub.11, then R.sub.10 and R.sub.11 can be taken together with the nitrogen atom to which they are attached to form a heterocyclyl or heteroaryl group, each of which is substituted with 0, 1, 2, or 3 R.sub.12; R.sub.4 and R.sub.5 can be taken together with the carbon atoms to which they are attached to form a cycloalkyl, heterocyclyl, aryl, or heteroaryl group, each of which is independently substituted with 0, 1, 2, or 3 R.sub.12, R.sub.6 is selected from H, acyl, alkyl, amino, halo, CN, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, each of which is substituted with 0, 1, 2, or 3 R.sub.12, each R.sub.7 is independently selected from H, alkyl, alkenyl, alkynyl, alkoxy, amido, amino, carbonyl, ester, halo, CN, and NO.sub.2, each of which is substituted with 0, 1, 2, or 3 R.sub.12; and wherein any two adjacent R.sub.7 groups can be taken together with the carbon atoms to which they are attached to form a cycloalkyl, heterocyclyl, aryl, or heteroaryl ring, each of which is substituted with 0, 1, 2, or 3 R.sub.12; R.sub.8 is selected from H, acyl, alkyl, amido, amino, carbamate, carbonyl, and urea, each of which is substituted with 0, 1, 2, or 3 R.sub.12; R.sub.9 is selected from H, alkyl, alkenyl, alkynyl, alkoxy, amino, amido, ester, halo, CN, NO.sub.2, cycloalkyl, heterocyclyl, aryl, and heteroaryl, each of which is substituted with 0, 1, 2, or 3 R.sub.12; each R.sub.10 and R.sub.11 are independently selected from H, acyl, alkyl, carbonyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, each of which is independently substituted with 0, 1, 2, or 3 R.sub.12; and each R.sub.12 is independently selected from acyl, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, alkoxycarbonyl, amido, amino, carbonate, carbamate, carbonyl, ester, halo, CN, NO.sub.2, hydroxyl, phosphate, phosphonate, phosphinate, phosphine oxide, urea, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl. 2. The compound according to claim 1, wherein X.sub.1 is carbon substituted by a group that is ##STR01265## 3. The compound according to claim 1, wherein X.sub.1 is carbon substituted by a group selected from ##STR01266## 4. The compound according to claim 1, wherein X.sub.2 is N; and/or X.sub.3 is CR.sub.4 and R.sub.4 is H. 5. The compound according to claim 1, wherein A is ##STR01267## optionally wherein X.sub.4 is CR.sub.7, where R.sub.7 is selected from H, alkyl, alkoxy, amido, ester, cyclohexyl, and CN; or X.sub.6 is CR.sub.9, and R.sub.9 is selected from H, heterocyclyl, aryl, and heteroaryl, each of which is substituted with 0, 1, or 2 R.sub.12. 6. The compound of claim 1, wherein A is selected from ##STR01268## or R.sub.3 is selected from H, alkyl, alkoxy, and halo; or R.sub.5 is --NR.sub.10R.sub.11, R.sub.10 is alkyl, R.sub.11 is alkyl substituted with one R.sub.12, and R.sub.12 is amino; or R.sub.6 is selected from H and alkyl substituted with one R.sub.12, and R.sub.12 is amino. 7. The compound according to claim 1, wherein R.sub.5 is selected from ##STR01269## ##STR01270## ##STR01271## 8. The compound according to claim 1, wherein: (1) A is selected from ##STR01272## X.sub.1 is carbon substituted by ##STR01273## X.sub.2 is N; X.sub.3 is CR.sub.4; R.sub.1 is selected from alkyl and heterocyclyl; R.sub.3 is alkoxy; R.sub.4 is H; R.sub.5 is --NR.sub.10R.sub.11, R.sub.6 is H; R.sub.8 is alkyl; R.sub.10 is alkyl, and R.sub.11 is alkyl substituted with one R.sub.12, and Rig is amino or heterocyclyl or (2) A is selected from ##STR01274## X.sub.1 is carbon substituted by ##STR01275## X.sub.2 is N; X.sub.3 is CR.sub.4; X.sub.4 is selected from N and CR.sub.7; R.sub.1 is alkyl, cycloalkyl, and heterocyclyl; R.sub.3 is alkoxy; R.sub.4 is H; R.sub.5 is --NR.sub.10R.sub.11, R.sub.6 is H; R.sub.7 is selected from H and alkoxy; R.sub.8 is selected from H and alkyl; R.sub.10 is alkyl, and R.sub.11 is alkyl substituted with one R.sub.12, and R.sub.12 is amino or heterocyclyl; or (4) A is ##STR01276## X.sub.1 is carbon substituted by ##STR01277## X.sub.2 is N; X.sub.3 is CR.sub.4; R.sub.1 is alkyl; R.sub.3 and R.sub.4 are taken together with the carbon atoms to which they are attached to form a cycloalkyl or heterocyclyl group; R.sub.5 is --NR.sub.10R.sub.11 R.sub.6 is H; R.sub.10 is alkyl, and R.sub.11 is alkyl substituted with one R.sub.12, and R.sub.12 is amino. 9. The compound according to claim 1, wherein the compound of Formula I is a compound selected from: Sec-butyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isobutyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(7-methoxy-1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Cyclopropylmethyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Cyclobutyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidine-5-carboxylate; Methyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Oxetan-3-yl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidine-5-carboxylat- e; Isopropyl 2-((5-acrylamido-2-methoxy-4-(methyl((1-methylpyrrolidin-2-yl)methyl)amin- o)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Ethyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H- -indol-3-yl)-5-pivalamidopyrimidin-2-yl)amino)phenyl)acrylamide; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(1H-indol-1-yl)pyrimidine-5-carboxylate; Isopropyl 2-((5-acrylamido-2-methoxy-4-(methyl(2-(methylamino)ethyl)-amino)phenyl)a- mino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; N-(2-((2-(dimethylamino)ethyl)(methyl)-amino)-4-methoxy-5-((4-(1-methyl-1- H-indol-3-yl)-5-(N-methylisobutyramido)-pyrimidin-2-yl)amino)phenyl)acryla- mide; N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((5-isobutyramido-4-(- 1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-me- thoxyphenyl)amino)-4-(1H-indol-3-yl)pyrimidine-5-carboxylate; Methyl 2-((5-acrylamido-2-methoxy-4-(methyl((1-methylpyrrolidin-2-yl)methyl)amin- o)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-me- thoxyphenyl)amino)-4-(1-methyl-1H-indazol-3-yl)pyrimidine-5-carboxylate; N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H- -indazol-3-yl)-5-propionamidopyrimidin-2-yl)amino)phenyl)acrylamide; Isopropyl (R)-2-((5-acrylamido-2-methoxy-4-(methyl((1-methylpyrrolidin-2-- yl)methyl)amino)phenyl)amino)-4-(1H-indol-1-yl)pyrimidine-5-carboxylate; Isopropyl (R)-2-((5-acrylamido-2-methoxy-4-(methyl((1-methylpyrrolidin-2-- yl)methyl)amino)phenyl)amino)-4-(benzofuran-3-yl)pyrimidine-5-carboxylate; Methyl (R)-2-((5-acrylamido-2-methoxy-4-(methyl((1-methylpyrrolidin-2-yl)- methyl)amino)phenyl)amino)-4-(1H-indol-1-yl)pyrimidine-5-carboxylate; Isopropyl (R)-2-((5-acrylamido-2-methoxy-4-(methyl((1-methylpyrrolidin-2-- yl)methyl)amino)phenyl)amino)-4-(1H-indol-3-yl)pyrimidine-5-carboxylate; Ethyl (R)-2-((5-acrylamido-2-methoxy-4-(methyl((1-methylpyrrolidin-2-yl)m- ethyl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxyla- te; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-((5-acrylamido-4-(2-(dimethylamino)ethoxy)-2-methoxyphenyl)am- ino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Methyl 2-((5-acrylamido-4-(3-(dimethylamino)prop-1-yn-1-yl)-2-methoxyphenyl)amin- o)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Methyl 2-((5-acrylamido-4-(3-(dimethylamino)propyl)-2-methoxyphenyl)amino)-4-(1-- methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; N-(5-((4-(1-(2-amino-2-oxoethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((- 2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; N-(5-((4-(1-(2-amino-2-oxoethyl)-1H-indol-3-yl)-5-ethylpyrimidin-2-yl)ami- no)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((5-ethyl-4-(1-(2-(methyla- mino)-2-oxoethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)acry- lamide; Methyl 2-((5-acrylamido-4-fluoro-2-methoxyphenyl)amino)-4-(1-(dimethylamino)-1H-- indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-((5-acrylamido-2-methoxy-4-(methyl(2-(methylamino)ethyl)amino)phenyl)am- ino)-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidine-5-carboxylate; Methyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-metho- xyphenyl)amino)-4-(1-(dimethylamino)-1H-indol-3-yl)pyrimidine-5-carboxylat- e; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(1-ethyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 4-(1-acetyl-1H-indol-3-yl)-2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(m- ethyl)amino)-2-methoxyphenyl)amino)pyrimidine-5-carboxylate; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(1-cyclopropyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Methyl 3-(2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyph- enyl)amino)pyrimidin-4-yl)-1-methyl-1H-indole-4-carboxylate; Methyl 3-(2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyph- enyl)amino)pyrimidin-4-yl)-1-methyl-1H-indole-5-carboxylate; Methyl 3-(2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyph- enyl)amino)pyrimidin-4-yl)-1-methyl-1H-indole-6-carboxylate; Isopropyl 3-(2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyph- enyl)amino)pyrimidin-4-yl)-1-methyl-1H-indole-6-carboxylate; Isopropyl 3-(2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyph- enyl)amino)pyrimidin-4-yl)-1-methyl-1H-indole-7-carboxylate; Methyl 3-(2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyph- enyl)amino)pyrimidin-4-yl)-1-methyl-1H-indole-2-carboxylate; Isopropyl 3-(2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyph- enyl)amino)pyrimidin-4-yl)-1-methyl-1H-indole-2-carboxylate; N-(5-((4-(2-cyano-1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dim- ethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; N-(5-((4-(6-cyano-1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dim- ethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; 3-(2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyph- enyl)amino)pyrimidin-4-yl)-1-methyl-1H-indole-2-carboxamide; 3-(2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyph- enyl)amino)pyrimidin-4-yl)-N,1-dimethyl-1H-indole-2-carboxamide; 3-(2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyph- enyl)amino)pyrimidin-4-yl)-N,N,1-trimethyl-1H-indole-2-carboxamide; 3-(2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyph- enyl)amino)pyrimidin-4-yl)-N-(2-methoxyethyl)-1-methyl-1H-indole-2-carboxa- mide; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidine-5-carboxylate; N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-6-- (1-methyl-1H-pyrazol-4-yl)-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acryl- amide; N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((5-(dimethylphospho- ryl)-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)acryl- amide; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(3-methyl-1H-indol-1-yl)pyrimidine-5-carboxylate; N-(5-((5-cyano-4-(1-methyl-1H-indazol-3-yl)pyrimidin-2-yl)amino)-2-((2-(d- imethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H- -indol-3-yl)-5-(3-methylureido)pyrimidin-2-yl)amino)phenyl)acrylamide; and N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-2-- ((2-oxoazetidin-1-yl)methyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acr- ylamide; or a pharmaceutically acceptable form thereof. 10. The compound according to claim 1, wherein the compound of Formula I is a compound selected from: Methyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(1H-indol-1-yl)pyrimidine-5-carboxylate; Isopropyl 2-((5-acrylamido-2-methoxy-4-(methyl((1-methylpyrrolidin-2-yl)methyl)amin- o)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isobutyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-met- hoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-me- thoxyphenyl)amino)-4-(7-methoxy-1-methyl-1H-indol-3-yl)pyrimidine-5-carbox- ylate; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidine-5-carboxylat- e; Isopropyl 2-((5-acrylamido-2-methoxy-4-(methyl(2-(methylamino)ethyl)-amino)phenyl)a- mino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Ethyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(1H-indol-3-yl)pyrimidine-5-carboxylate; (S)-Isopropyl 2-((5-acrylamido-2-methoxy-4-(methyl((1-methylpyrrolidin-2-yl)methyl)amin- o)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; (R)-Isopropyl 2-((5-acrylamido-2-methoxy-4-(methyl((1-methylpyrrolidin-2-yl)methyl)amin- o)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; N-(5-((5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylami- no)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-((5-acrylamido-4-(2-(dimethylamino)ethoxy)-2-methoxyphenyl)am- ino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; and Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxypheny- l)amino)-4-(1-ethyl-1H-indol-3-yl)pyrimidine-5-carboxylate; or a pharmaceutically acceptable form thereof. 11. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable carrier, diluent, or vehicle. 12. A method for treating cancer associated with one or more insertion or deletion mutations in the exon 20 domain of EGFR or HER2, comprising administering to a subject in a subject in need thereof, a therapeutically effective amount of a compound of Formula I according to claim 1, or a pharmaceutically acceptable form thereof, wherein the cancer is non-small cell lung cancer (NSCLC). 13. The method according to claim 12, wherein the subject is resistant to a kinase inhibitor other than a compound of Formula I, optionally wherein the kinase inhibitor is an EGFR inhibitor or a HER2 inhibitor. 14. A method for inhibiting EGFR or HER2, or a mutation thereof, in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable form thereof, optionally wherein the mutation is in the exon 20 domain of EGFR or the mutation is in the exon 20 domain of HER2.